drugset

drugset / Trial / NCT06423781

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

NCT06423781 ↗

Phase 2 Completed 233 enrolled Biohaven Therapeutics Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Timeline

Start: 2024-08-01
Primary completion: 2026-03-18
Completion: 2026-03-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BHV-7000	Unknown	75 mg	—

Indications